Evidence map›Paper›PMID 34337900›Full record

ArticlePhysiological reports2021

Temporal regulation of protein O-GlcNAc levels during pressure-overload cardiac hypertrophy.

Wei Zhong Zhu, Dolena Ledee, Aaron K Olson

Open access · goldAbstract read
In one paragraph

Article in Physiological reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Best practices in assessing cardiac proteinAmerican journal of physiology. Heart and circulatory physiology · 2023
    Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Cardiomyocyte protein O-GlcNAcylation is regulated by GFAT1 not GFAT2.Biochemical and biophysical research communications · 2021
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Wei Zhong ZhuSeattle Children's Research Institute, Seattle, WA, USA.
Dolena LedeeSeattle Children's Research Institute, Seattle, WA, USA.
Aaron K OlsonSeattle Children's Research Institute, Seattle, WA, USA.ORCID 0000-0002-5237-400X
University of Washington · US

Funding

Metabolic regulation of O-GlcNAc and cardiac function during hypertrophyR01HL122546 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI OLSON, AARON K · 2015 to 2019
$2.7M
Regulation Mechanisms of Thyroid Hormone Receptors in the HeartK01HL120886 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI LEDEE, DOLENA ROSELLE · 2014 to 2018
$723k
NHLBI NIH HHS K01 HL120886NHLBI NIH HHS R01 HL122546
6 · The paper itself

Abstract

Protein posttranslational modifications (PTMs) by O-linked β-N-acetylglucosamine (O-GlcNAc) rise during pressure-overload hypertrophy (POH) to affect hypertrophic growth. The hexosamine biosynthesis pathway (HBP) branches from glycolysis to make the moiety for O-GlcNAcylation. It is speculated that greater glucose utilization during POH augments HBP flux to increase O-GlcNAc levels; however, recent results suggest glucose availability does not primarily regulate cardiac O-GlcNAc levels. We hypothesize that induction of key enzymes augment protein O-GlcNAc levels primarily during active myocardial hypertrophic growth and remodeling with early pressure overload. We further speculate that downregulation of protein O-GlcNAcylation inhibits ongoing hypertrophic growth during prolonged pressure overload with established hypertrophy. We used transverse aortic constriction (TAC) to create POH in C57/Bl6 mice. Experimental groups were sham, 1-week TAC (1wTAC) for early hypertrophy, or 6-week TAC (6wTAC) for established hypertrophy. We used western blots to determine O-GlcNAc regulation. To assess the effect of increased protein O-GlcNAcylation with established hypertrophy, mice received thiamet-g (TG) starting 4 weeks after TAC. Protein O-GlcNAc levels were significantly elevated in 1wTAC versus Sham with a fall in 6wTAC. OGA, which removes O-GlcNAc from proteins, fell in 1wTAC versus sham. GFAT is the rate-limiting HBP enzyme and the isoform GFAT1 substantially rose in 1wTAC. With established hypertrophy, TG increased protein O-GlcNAc levels but did not affect cardiac mass. In summary, protein O-GlcNAc levels vary during POH with elevations occurring during active hypertrophic growth early after TAC. O-GlcNAc levels appear to be regulated by changes in key enzyme levels. Increasing O-GlcNAc levels during established hypertrophy did not restart hypertrophic growth.

Indexed as

Biosynthetic PathwaysPressureProtein Processing, Post-TranslationalAnimalsCardiomegalyGlycoproteinsGlycosylationMiceMice, Inbred C57BLGlycoproteinsCardiac hypertrophyGFATglucose metabolismhexosamine biosynthesis pathwayO-GlcNAcpressure-overload hypertrophythiamet-gtransverse aortic constriction

Identifiers

PMID34337900
PMCPMC8326887
OpenAlexW3188474217

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.